600566 济川药业
已收盘 05-07 15:00:00
资讯
新帖
简况
济川药业（600566）披露回购股份进展公告，5月7日股价上涨1.79%
证券之星 · 05-07 22:56
济川药业（600566）披露回购股份进展公告，5月7日股价上涨1.79%
券商重仓路径曝光：去年单股最高持仓超百亿，一季度新进百余股
第一财经 · 05-07 20:42
券商重仓路径曝光：去年单股最高持仓超百亿，一季度新进百余股
济川药业最新公告：健胃消食口服液拟中选全国中成药集中带量采购
证券之星 · 05-07 17:49
济川药业最新公告：健胃消食口服液拟中选全国中成药集中带量采购
每周股票复盘：济川药业（600566）股东户数降11.25%，一季报营收下滑20.84%
证券之星 · 04-26
每周股票复盘：济川药业（600566）股东户数降11.25%，一季报营收下滑20.84%
4月24日济川药业涨6.16%，国泰大健康股票A基金重仓该股
证券之星 · 04-24
4月24日济川药业涨6.16%，国泰大健康股票A基金重仓该股
图解济川药业年报：第四季度单季净利润同比增长20.15%
证券之星 · 04-24
图解济川药业年报：第四季度单季净利润同比增长20.15%
济川药业拟每股派发现金红利1.74元，现金分红率89.94%
财中社 · 04-23
济川药业拟每股派发现金红利1.74元，现金分红率89.94%
每周股票复盘：济川药业（600566）一季度行权31.8万股
证券之星 · 04-05
每周股票复盘：济川药业（600566）一季度行权31.8万股
济川药业（600566）披露2022年激励计划2026年第一季度自主行权结果暨股本变动公告，4月3日股价下跌1.73%
证券之星 · 04-03
济川药业（600566）披露2022年激励计划2026年第一季度自主行权结果暨股本变动公告，4月3日股价下跌1.73%
每周股票复盘：济川药业（600566）设限行权期至4月29日
证券之星 · 03-29
每周股票复盘：济川药业（600566）设限行权期至4月29日
济川药业（600566）披露2022年股权激励计划限制行权期间提示性公告，3月27日股价下跌3.36%
证券之星 · 03-27
济川药业（600566）披露2022年股权激励计划限制行权期间提示性公告，3月27日股价下跌3.36%
每周股票复盘：济川药业（600566）回购进展支付超2500万元
证券之星 · 03-08
每周股票复盘：济川药业（600566）回购进展支付超2500万元
济川药业（600566）披露全资子公司使用闲置募集资金进行现金管理进展，3月6日股价上涨0.84%
证券之星 · 03-06
济川药业（600566）披露全资子公司使用闲置募集资金进行现金管理进展，3月6日股价上涨0.84%
济川药业（600566）披露回购股份进展公告，3月3日股价上涨2.01%
证券之星 · 03-03
济川药业（600566）披露回购股份进展公告，3月3日股价上涨2.01%
每周股票复盘：济川药业（600566）获泽立美独家商业化权
证券之星 · 03-01
每周股票复盘：济川药业（600566）获泽立美独家商业化权
济川药业（600566）披露部分独立董事任期届满提示性公告，2月27日股价上涨0.83%
证券之星 · 02-27
济川药业（600566）披露部分独立董事任期届满提示性公告，2月27日股价上涨0.83%
济川药业最新公告：全资子公司签署独占性商业化权益协议
证券之星 · 02-26
济川药业最新公告：全资子公司签署独占性商业化权益协议
瞄准过敏性鼻炎新药！济川药业“牵手”普祺医药，后者正冲刺港股IPO
市场资讯 · 02-03
瞄准过敏性鼻炎新药！济川药业“牵手”普祺医药，后者正冲刺港股IPO
康方生物(09926)授予济川药业伊喜宁®的独家商业化权益
智通财经 · 02-03
康方生物(09926)授予济川药业伊喜宁®的独家商业化权益
济川药业（600566）披露以集中竞价交易方式回购股份的进展公告，2月2日股价下跌1.8%
证券之星 · 02-02
济川药业（600566）披露以集中竞价交易方式回购股份的进展公告，2月2日股价下跌1.8%
加载更多
公司概况
公司名称：
湖北济川药业股份有限公司
所属行业：
医药制造业
上市日期：
2001-08-22
主营业务：
湖北济川药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是小儿豉翘清热颗粒、糖浆剂型、蒲地蓝消炎口服液、黄龙止咳颗粒、三拗片、健胃消食口服液、硫酸镁钠钾口服用浓溶液、甘海胃康胶囊、妇炎舒胶囊、蛋白琥珀酸铁口服溶液。2025年7月，“2024年度中国医药工业主营业务收入前100位企业”名单在第42届全国医药工业信息年会上发布，济川控股位列榜单第42位。
发行价格：
7.80
{"stockData":{"symbol":"600566","market":"SH","secType":"STK","nameCN":"济川药业","latestPrice":28.36,"timestamp":1778137200000,"preClose":27.86,"halted":0,"volume":7249819,"delay":0,"changeRate":0.0179,"floatShares":919000000,"shares":922000000,"eps":1.8854,"marketStatus":"已收盘","change":0.5,"latestTime":"05-07 15:00:00","open":27.86,"high":28.45,"low":27.82,"amount":205000000,"amplitude":0.0226,"askPrice":28.38,"askSize":4,"bidPrice":28.36,"bidSize":196,"shortable":0,"etf":0,"ttmEps":1.8854,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778203800000},"marketStatusCode":5,"adr":0,"adjPreClose":27.86,"symbolType":"stock","openAndCloseTimeList":[[1778117400000,1778124600000],[1778130000000,1778137200000]],"highLimit":30.65,"lowLimit":25.07,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":921662260,"isCdr":false,"pbRate":1.74,"roa":"--","peRate":15.041901,"roe":"2.7%","epsLYR":1.93,"committee":0.174349,"marketValue":26138000000,"turnoverRate":0.0079,"status":0,"floatMarketCap":26050000000},"requestUrl":"/m/hq/s/600566","defaultTab":"news","newsList":[{"id":"2633260501","title":"济川药业（600566）披露回购股份进展公告，5月7日股价上涨1.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633260501","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633260501?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:56","pubTimestamp":1778165773,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘，济川药业报收于28.36元，较前一交易日上涨1.79%，最新总市值为261.38亿元。该股当日开盘27.86元，最高28.45元，最低27.82元，成交额达2.05亿元，换手率为0.79%。近日，湖北济川药业股份有限公司发布《关于以集中竞价交易方式回购股份的进展公告》。2026年4月未实施回购。上述回购符合相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700041704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600566","BK0188","BK0077","BK0028","BK0201","BK0012","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633128612","title":"券商重仓路径曝光：去年单股最高持仓超百亿，一季度新进百余股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633128612","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633128612?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:42","pubTimestamp":1778157720,"startTime":"0","endTime":"0","summary":" “易中天”热度持续高涨，龙头券商也买进了前十大股东。 随着年报和一季报披露完毕，券商重仓路径浮现，在A股市场震荡上行中，哪些个股成为券商的“心头好”？ 第一财经根据Choice数据统计，截至去年年底，券商现身近300家A股公司的前十大流通股股东名单，合计持股总市值超700亿元。其中，截至去年年底，中信证券对中信建投的持仓市值超过百亿元。 随着一季报披露收官，券商最新调仓换股路径同步曝光。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-07/doc-inhxatff4721846.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-07/doc-inhxatff4721846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0198","LU0359202008.SGD","BK0187","002252","000408","002714","BK0056","600863","300532","BK0252","BK0046","BK0196","601658","LU2778985437.USD","BK0197","300502","BK0182","300182","SGXZ81163826.USD","LU2399975544.HKD","LU1979443071.USD","BK0077","LU1655091616.SGD","02714","601066","BK0108","BK0012","BK0201","BK0214","000670","600919","LU1794554557.SGD","BK0127","301314","600566","SGXZ49509284.SGD","600927","LU1961090484.USD","BK0015","002911","BK0070","BK0132","BK0189","BK0195","BK0125","BK0155","BK0109","603817","LU2495084118.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633112842","title":"济川药业最新公告：健胃消食口服液拟中选全国中成药集中带量采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2633112842","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633112842?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:49","pubTimestamp":1778147395,"startTime":"0","endTime":"0","summary":"济川药业(600566.SH)公告称，全资子公司济川有限参与了全国中成药采购联盟集中带量采购工作，根据拟中选结果公示，济川有限产品健胃消食口服液拟中选此次集中带量采购。上述拟中选产品健胃消食口服液2025年度销售收入约4.54亿元，占公司2025年度营业收入总额的比例为7.29%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700030025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0239","BK0012","BK0188","600566","BK0077","BK0028","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630804511","title":"每周股票复盘：济川药业（600566）股东户数降11.25%，一季报营收下滑20.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630804511","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630804511?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:30","pubTimestamp":1777145431,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，济川药业报收于26.7元，较上周的24.9元上涨7.23%。本周，济川药业4月24日盘中最高价报26.85元。济川药业当前最新总市值246.08亿元，在中药板块市值排名9/66，在两市A股市值排名871/5200。业绩披露要点：2026年一季报主营收入12.07亿元，同比下降20.84%。股本股东变化截至2026年3月31日，公司股东户数为3.26万户，较2025年12月31日减少4136户，减幅11.25%。因8名激励对象离职，注销股票期权33.85万份，回购注销限制性股票33.85万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629381618","title":"4月24日济川药业涨6.16%，国泰大健康股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629381618","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629381618?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:24","pubTimestamp":1777019050,"startTime":"0","endTime":"0","summary":"证券之星消息，4月24日济川药业涨6.16%，收盘报26.7元，换手率1.6%，成交量14.69万手，成交额3.88亿元。重仓济川药业的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为国泰基金的国泰大健康股票A。国泰大健康股票A目前规模为2.57亿元，最新净值2.116，较上一交易日下跌1.31%，近一年上涨10.84%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400049619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","BK0239","600566","BK0012","BK0201","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629851414","title":"图解济川药业年报：第四季度单季净利润同比增长20.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629851414","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629851414?lang=zh_cn&edition=full","pubTime":"2026-04-24 00:55","pubTimestamp":1776963302,"startTime":"0","endTime":"0","summary":"证券之星消息，济川药业2025年年报显示，当年度公司主营收入62.19亿元，同比下降22.43%；归母净利润17.78亿元，同比下降29.77%；扣非净利润15.61亿元，同比下降31.1%；其中2025年第四季度，公司单季度主营收入22.87亿元，同比上升3.38%；单季度归母净利润7.55亿元，同比上升20.15%；单季度扣非净利润7.02亿元，同比上升23.88%；负债率17.33%，投资收益1.9亿元，财务费用-5449.2万元，毛利率78.95%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400002286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629858416","title":"济川药业拟每股派发现金红利1.74元，现金分红率89.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629858416","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629858416?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:57","pubTimestamp":1776952620,"startTime":"0","endTime":"0","summary":"4月23日，济川药业（600566）发布公告，公司拟向全体股东每股派发现金红利1.74元（含税），预计总派发金额为15.99亿元，占2025年合并报表归母净利润的89.94%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/zqgd/2026-04-23/doc-inhvpcus4853684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK4585","VIG","BK0187","BK0239","600566","BK0012","BK0188","BK4588","BK0077","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625619643","title":"每周股票复盘：济川药业（600566）一季度行权31.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625619643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625619643?lang=zh_cn&edition=full","pubTime":"2026-04-05 03:00","pubTimestamp":1775329235,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，济川药业报收于26.68元，较上周的25.63元上涨4.1%。公司公告汇总湖北济川药业股份有限公司发布2022年限制性股票与股票期权激励计划2026年第一季度自主行权结果暨股本变动公告。2026年第一季度行权并完成过户登记的股份为318,000股，截至2026年第一季度末累计行权1,173,400股。股本结构方面，无限售条件股份增加318,000股，总股本相应增加，实际控制人未发生变化。湖北济川药业股份有限公司关于以集中竞价交易方式回购股份的进展公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0201","600566","BK0012","BK0077","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624651622","title":"济川药业（600566）披露2022年激励计划2026年第一季度自主行权结果暨股本变动公告，4月3日股价下跌1.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624651622","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624651622?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:11","pubTimestamp":1775211074,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，济川药业报收于26.68元，较前一交易日下跌1.73%，最新总市值为245.9亿元。湖北济川药业股份有限公司近日发布《关于2022年限制性股票与股票期权激励计划2026年第一季度自主行权结果暨股本变动公告》。公告显示，2026年第一季度行权并完成过户登记的股份为318,000股，截至2026年第一季度末累计行权1,173,400股。本次行权采用自主行权模式，行权所得股票于行权日后的第二个交易日上市交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300035261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","BK0187","BK0077","BK0028","600566","BK0188","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623333835","title":"每周股票复盘：济川药业（600566）设限行权期至4月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=2623333835","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623333835?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:54","pubTimestamp":1774727651,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，济川药业报收于25.63元，较上周的28.39元下跌9.72%。本周，济川药业3月23日盘中最高价报28.45元。公司公告汇总湖北济川药业股份有限公司关于2022年限制性股票与股票期权激励计划首次授予股票期权限制行权期间的提示性公告湖北济川药业股份有限公司根据相关规定，对2022年限制性股票与股票期权激励计划首次授予股票期权设置限制行权期。本次限制行权期间为2026年4月3日至2026年4月29日，在此期间所有激励对象将限制行权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0012","600566","BK0201","BK0239","BK0077","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622661878","title":"济川药业（600566）披露2022年股权激励计划限制行权期间提示性公告，3月27日股价下跌3.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622661878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622661878?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:29","pubTimestamp":1774621788,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，济川药业报收于25.63元，较前一交易日下跌3.36%，最新总市值为236.14亿元。近日，湖北济川药业股份有限公司发布《关于2022年限制性股票与股票期权激励计划首次授予股票期权限制行权期间的提示性公告》。公告显示，该激励计划第一个行权期实际可行权时间为2025年10月15日至2026年9月7日；本次限制行权期间为2026年4月3日至2026年4月29日，在此期间所有激励对象将限制行权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700050226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0077","BK0188","BK0187","BK0239","BK0028","600566","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617663804","title":"每周股票复盘：济川药业（600566）回购进展支付超2500万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663804","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617663804?lang=zh_cn&edition=full","pubTime":"2026-03-08 03:00","pubTimestamp":1772910038,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，济川药业报收于27.75元，较上周的27.79元下跌0.14%。本周，济川药业3月3日盘中最高价报28.5元。2026年2月回购184,700股，支付金额5,046,056元。湖北济川药业股份有限公司全资子公司使用闲置募集资金10,000万元进行现金管理，分别购买平安证券、苏州银行和渤海银行的保本浮动收益型产品，期限分别为69天、66天和72天。截至公告日，前次现金管理已全部赎回，收回本金12,000万元，取得收益合计约118.62万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0201","600566","BK0012","BK0077","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617636033","title":"济川药业（600566）披露全资子公司使用闲置募集资金进行现金管理进展，3月6日股价上涨0.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617636033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617636033?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:56","pubTimestamp":1772808974,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，济川药业报收于27.75元，较前一交易日上涨0.84%，最新总市值为255.67亿元。近日，湖北济川药业股份有限公司发布《关于全资子公司利用闲置募集资金进行现金管理的进展公告》。公告显示，公司全资子公司使用闲置募集资金10,000万元进行现金管理，分别购买平安证券、苏州银行和渤海银行的保本浮动收益型产品，期限分别为69天、66天和72天。截至公告日，前次现金管理已全部赎回，收回本金12,000万元，取得收益合计约118.62万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600040724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600566","BK0012","BK0077","BK0201","BK0239","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616326020","title":"济川药业（600566）披露回购股份进展公告，3月3日股价上涨2.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616326020","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616326020?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:28","pubTimestamp":1772548102,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，济川药业报收于28.36元，较前一交易日上涨2.01%，最新总市值为261.29亿元。该股当日开盘27.78元，最高28.5元，最低27.58元，成交额达3.14亿元，换手率为1.21%。近日，湖北济川药业股份有限公司发布《关于以集中竞价交易方式回购股份的进展公告》。截至2026年2月28日，公司已累计回购934,700股，占总股本的0.10%，累计支付金额25,000,953元，回购价格区间为25.94元/股至27.49元/股。2026年2月回购184,700股，支付金额5,046,056元。上述回购符合相关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300044492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","BK0187","BK0077","BK0028","600566","BK0188","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616184524","title":"每周股票复盘：济川药业（600566）获泽立美独家商业化权","url":"https://stock-news.laohu8.com/highlight/detail?id=2616184524","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616184524?lang=zh_cn&edition=full","pubTime":"2026-03-01 03:07","pubTimestamp":1772305628,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，济川药业报收于27.79元，较上周的27.18元上涨2.24%。本周，济川药业2月27日盘中最高价报28.02元。济川药业当前最新总市值256.04亿元，在中药板块市值排名10/67，在两市A股市值排名873/5189。本周关注点公司公告汇总：济川药业全资子公司获得泽立美本维莫德乳膏中国大陆地区独家商业化权利。湖北济川药业股份有限公司独立董事姚宏、卢超军自2020年3月2日起任职，即将满六年，根据相关规定申请辞职。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600566","BK0077","BK0012","BK0187","BK0028","BK0188","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614850015","title":"济川药业（600566）披露部分独立董事任期届满提示性公告，2月27日股价上涨0.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614850015","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614850015?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:35","pubTimestamp":1772206515,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，济川药业报收于27.79元，较前一交易日上涨0.83%，最新总市值为256.04亿元。该股当日开盘27.72元，最高28.02元，最低27.53元，成交额达9035.8万元，换手率为0.35%。近日，湖北济川药业股份有限公司发布关于部分独立董事任期届满的提示性公告。因任期届满离任将导致独立董事人数低于董事会成员三分之一，在换届完成前，二人将继续履职至新任独立董事选举产生。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700043422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","600566","BK0187","BK0201","BK0012","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614019884","title":"济川药业最新公告：全资子公司签署独占性商业化权益协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2614019884","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614019884?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:24","pubTimestamp":1772097857,"startTime":"0","endTime":"0","summary":"济川药业(600566.SH)公告称，全资子公司济川有限与泽德曼签署独占性商业化权益协议，泽德曼授权济川有限在合作期限内独家负责其拥有的泽立美本维莫德乳膏在中国大陆地区（不包含香港、澳门和台湾地区）的商业化。济川有限支付的首付款及里程碑付款将不超过1.9亿元（含税）。泽立美本维莫德乳膏是我国自主研发也是全球首个被批准用于2岁及以上儿童与成人湿疹（特应性皮炎）治疗的芳香烃受体（AhR）调节剂，可通过抑制炎症、修复皮肤屏障、调节菌群和抗氧化应激发挥治疗作用。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600026467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","BK0077","600566","BK0187","BK0012","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608389714","title":"瞄准过敏性鼻炎新药！济川药业“牵手”普祺医药，后者正冲刺港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2608389714","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608389714?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:09","pubTimestamp":1770127740,"startTime":"0","endTime":"0","summary":" 济川药业将布局瞄准过敏性鼻炎新药。 2月3日，济川药业发布公告称，公司全资子公司济川药业集团有限公司与北京普祺医药科技股份有限公司签署独家商业化合作协议，约定授权济川有限在合作期限内独家负责普祺医药拥有的普美昔替尼鼻喷雾剂在中国的商业化。 值得一提的是，普美昔替尼的研发方普祺医药，目前正在冲刺港股IPO。这也意味着，此次商业授权将给普祺医药带来一笔不菲的收入。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-03/doc-inhkqfvf4193850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0012","BK0028","09939","BK0077","BK0187","BK0201","BK4588","159938","600566","VT","BK4585","VXUS","BK1161","BK1574","BK0188","BK0239","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608820376","title":"康方生物(09926)授予济川药业伊喜宁®的独家商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2608820376","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608820376?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:13","pubTimestamp":1770117191,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方(广东)医药有限公司与湖北济川药业股份有限公司全资子公司济川药业集团有限公司、江苏济源医药有限公司于近日签署《独占性商业化权益协议》，康方生物授权济川药业在合作期限内，在中华人民共和国拥有公司自主开发并已获批上市的伊喜宁的独家商业化权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B543WZ88.USD","BK0077","LU0417516738.SGD","LU1720050803.USD","LU0348766576.USD","BK0187","IE00B5MMRT66.SGD","LU0348735423.USD","LU0348767384.USD","LU1794554557.SGD","LU2488822045.USD","LU0540923850.HKD","LU2778985437.USD","LU0417516902.SGD","IE00BPRC5H50.USD","BK0188","LU0348825331.USD","BK0201","LU0348827113.USD","LU0348784397.USD","BK0012","09926","LU2476274308.USD","LU1961090484.USD","BK1574","LU0348783233.USD","BK0239","600566","LU0634319403.HKD","LU0561508036.HKD","LU2399975544.HKD","BK0028","LU2476274720.SGD","BK1161","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608867960","title":"济川药业（600566）披露以集中竞价交易方式回购股份的进展公告，2月2日股价下跌1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608867960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608867960?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:23","pubTimestamp":1770042197,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，济川药业报收于25.59元，较前一交易日下跌1.8%，最新总市值为235.77亿元。近日，湖北济川药业股份有限公司发布《关于以集中竞价交易方式回购股份的进展公告》。公告显示，公司于2025年11月24日召开董事会，审议通过以集中竞价交易方式回购公司股份的方案，回购资金总额为2,500万元至5,000万元，用于员工持股计划或股权激励，回购价格不超过38元/股，实施期限为董事会审议通过后12个月内。上述回购进展符合相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600566","BK0012","BK0077","BK0201","BK0239","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778171513940,"stockEarnings":[{"period":"1week","weight":0.0242},{"period":"1month","weight":0.0862},{"period":"3month","weight":0.0582},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1407},{"period":"ytd","weight":0.0783}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0745},{"period":"3month","weight":0.0282},{"period":"6month","weight":0.0457},{"period":"1year","weight":0.2505},{"period":"ytd","weight":0.0532}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖北济川药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"32642人(较上一季度减少11.25%)","perCapita":"28140股","listingDate":"2001-08-22","address":"湖北省荆州市沙市区园林路时尚豪庭602室","registeredCapital":"92166万元","survey":" 湖北济川药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是小儿豉翘清热颗粒、糖浆剂型、蒲地蓝消炎口服液、黄龙止咳颗粒、三拗片、健胃消食口服液、硫酸镁钠钾口服用浓溶液、甘海胃康胶囊、妇炎舒胶囊、蛋白琥珀酸铁口服溶液。2025年7月，“2024年度中国医药工业主营业务收入前100位企业”名单在第42届全国医药工业信息年会上发布，济川控股位列榜单第42位。","listedPrice":7.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"济川药业(600566)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供济川药业(600566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"济川药业,600566,济川药业股票,济川药业股票老虎,济川药业股票老虎国际,济川药业行情,济川药业股票行情,济川药业股价,济川药业股市,济川药业股票价格,济川药业股票交易,济川药业股票购买,济川药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"济川药业(600566)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供济川药业(600566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}